Our Accessibility Statement | Terms of Service | Do Not Sell My Information. Amazing new therapeutics are very close to FDA Approval that will send shares flying. View analysts' price targets for Onconova Therapeutics or view top-rated stocks among Wall Street analysts. TVIX is a guarantee because of the inevitable degradation of the contracts and ONTX is a sure short bet because of the utter corruption of the management and the board. Only 1.00% of the stock of Onconova Therapeutics is held by insiders. 2 brokers have issued 1 year price objectives for Onconova Therapeutics' stock. A total of 28.75 . This is the fourth time this movie is playing yet nobody does anything about it! Onconova Therapeutics Institutional Ownership They are TVIX and ONTX. Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bluebird Bio (BLUE - Research Report), Onconova Therapeutics (ONTX - Research Report) and TherapeuticsMD (TXMD - Research Report).Bluebird Bio (BLUE) In a report released today, Zhiqiang Shu from Berenberg Bank reiterated a Hold rating on Bluebird Bio, with a price target of $11.00. This table shows the interest rate that must be paid by a short seller of US:ONTX to the lender of that security. Some companies that are related to Onconova Therapeutics include UroGen Pharma (URGN), Syros Pharmaceuticals (SYRS), Pieris Pharmaceuticals (PIRS), Landos Biopharma (LABP), FS Development Corp. II (FSII), Impel NeuroPharma (IMPL), Vincerx Pharma (VINC), Ovid Therapeutics (OVID), Matinas BioPharma (MTNB), Molecular Templates (MTEM), Paratek Pharmaceuticals (PRTK), Leap Therapeutics (LPTX), Neoleukin Therapeutics (NLTX), Avalo Therapeutics (AVTX) and CM Life Sciences III (CMLT). Onconova Therapeutics, Inc. Common Stock (ONTX) After ... According to the issued ratings of 2 analysts in the last year, the consensus rating for Onconova Therapeutics stock is Buy based on the current 2 buy ratings for ONTX. A high-level overview of Onconova Therapeutics, Inc. (ONTX) stock. MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. About Onconova Therapeutics, Inc. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. Conference call and live webcast at 4:30 p.m. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is . Company insiders that own Onconova Therapeutics stock include Abraham N Oler, Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin and Steven M Fruchtman. 10 Watchers. Onconova is developing a late-stage clinical asset and has run up 108% over the last month. Onconova Therapeutics, Inc. At least TVIX sometimes have temporary sharp rises (On days that the market is crashing). Onconova Therapeutic operates under Biotechnology classification in the United States and is traded on . Press question mark to learn the rest of the keyboard shortcuts Onconova Therapeutics prices $2.5 mln stock offering at $2.10 a share. Since then, ONTX stock has decreased by 48.7% and is now trading at $2.77. On average, they expect Onconova Therapeutics' share price to reach $11.50 in the next year. GlobeNewswire - 8:00 AM ET 09/24/2021. ONTX Stock News - Fidelity Onconova And The Conflict Lurking Beneath The Hype (NASDAQ ... November 21, 2019 - Onconova entered into a Distribution, License and Supply Agreement with Knight Therapeutics Inc., a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products. Want to see which stocks are moving? An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split. Onconova Therapeutics, Inc. The Company has . Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical companyfocused on discovering and developing products for patients with cancer. NEWTOWN, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering . Onconova Therapeutics Announces Presentation at the 25th ... ONTX / Onconova Therapeutics Inc short borrow fee rates are shown in the following table. ET by Ciara Linnane. Onconova Therapeutics' stock was trading at $5.40 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). © American Consumer News, LLC dba MarketBeat® 2010-2021. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. ONTX Institutional Ownership - Onconova Therapeutics Inc Stock Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. About Onconova Therapeutics, Inc. Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. OCGN 5.65 0.38 (6.30%) Post-Market 0.04 (0.71%) 154,437. Onconova Therapeutics has received 70.22% “outperform” votes from our community. Onconova Therapeutics has received 375 “outperform” votes. It isn't uncommon for clinical-stage pharma companies to witness high volatility . Key Data. The bears made the stock sink to a new 52-week low. See what's happening in the market right now with MarketBeat's real-time news feed. Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference. Onconova Therapeutics Inc. (ONTX) Stock Message Board ... According to analysts' consensus price target of $11.50, Onconova Therapeutics has a forecasted upside of 315.2% from its current price of $2.77. Be Cautious as Onconova Therapeutics Stock Flirts With De ... ONTX Stock Price | Onconova Therapeutics Inc. Stock Quote ... Phase 2 in Austria and England. Let me reiterate why I am invested in AGEN: ONTX, undercoverly working on the cure for gullibility since 1998. Headline. Onconova Therapeutics, Inc. (ONTX) Stock Forum ... The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. January 7, 2021 - 9:40 am. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Of all the stock advice services I have used, I find (. Description : Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. Time (ET) MT Newswires. As per Analysts prediction, this has 300% PLUS growth potential based on today's price. CEO Fruchtman won $10 on a scratch-off & will try to use that good news to pump ONTX. Please log in to your account or sign up in order to add this asset to your watchlist. Announces Pricing of $21 Million Public Offering of Common Stock. Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat for patients with cancer. A cool zombie with a tv for a dead I lost my tail here, but so glad I sold. I really thought it will be at least Christmas before $1 is reached and Fruchtman does his reverse split scam again. Onconova has remained active in fighting cancer, but ONTX stock only merits a small position size. As of November 15th, there was short interest totaling 348,500 shares, a drop of 20.5% from the October 31st total of 438,200 shares. The number of messages related to AMC on trading-focused social media site Stocktwits rose more than 7% on Wednesday, with most of them reflecting a positive sentiment. With the run up completed, Onconova represents a more risky bet with an upcoming binary event. They are pushing hard to do that even sooner. ONTX closed down 8.67 percent on Wednesday, December 1, 2021, on 16 percent of normal volume. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. In a press release yesterday, Onconova Therapeutics announced that it had completed a fund raise with gross proceeds of $28.75 million at $1 per share . Their forecasts range from $11.00 to $12.00. Are These 3 Old-School Companies Worth A Fresh Look? Strong Bullish Points: - Just moved above the cloud on daily - Strong support at 9ema supported by the top trendline - It's a pharma penny stock lottery! -8.67%. The Company has proprietary targeted anti-cancer . Shares of ONTX can be purchased through any online brokerage account. 52wk Low 0.29. The company's shares closed last Thursday at $2.80, close to its 52-week low of $2.72. Then again I wish I never had this 100K write off and cannot wait to sue. ONTX doesn't even have that. Wire. View our earnings forecast for Onconova Therapeutics. God, this has dropped 70040 dollars per share since 7 years ago. Catalysts: - CEO, Fruchtman, and CMO, Woodman, having both worked for Johnson and Johnson and Novartis - The two of them combined have brought 6 drugs through FDA approval The Pipeline: 1. Onconova Therapeutics has received a consensus rating of Buy. ONTX Stock Message Board for Investors. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is . By David Moadel, InvestorPlace . Onconova Therapeutics' stock is owned by a number of retail and institutional investors. Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. crudeoil24. Clinical trials with the Company's compound rigosertib are aimed at what the . •. The Schedule 13D indicates that the investor holds (or held) more . This suggests a possible upside of 315.2% from the stock's current price. Onconova Therapeutics had a negative trailing twelve-month return on equity of 59.78% and a negative net margin of 8,294.27%. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. F. 2.74. The most blatant fraud currently in the market as well as the best short play EVER. Onconova Therapeutics Inc. Stock Price, News and Company Updates. Below $1 and another reverse split/stock offering in record time. Ocugen NASDAQ Updated Dec 10, 2021 12:59 AM. Onconova Therapeutics, Inc. -0.26. Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. November 21, 2019 - Onconova entered into a Distribution, License and Supply Agreement with Knight Therapeutics Inc., a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products. According to the Agreement, Knight shall have . To see all exchange delays and terms of use please see disclaimer. The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) - a biopharmaceutical company focused on discovering and developing novel products to treat cancer - as of 11:17 PM ET. Post-Market 0.00 (0.00%) 26 May 2021 Rigosertib - Onconova Therapeutics is available for licensing as of 21 May 2021. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. View which stocks are hot on social media with MarketBeat's trending stocks report. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. Yes, cancer.-Has cash in hand to fund their trials for 18 months View which stocks have been most impacted by COVID-19. US electric vehicle charging network strategy being released, Satellite images, expert suggest Iranian space launch coming, The Trade Desk Stock Deserves a Second Look, 3 Dependable Dow Stocks to Buy in December, MarketBeat: Week in Review 12-6 – 12/10, Reasons to Invest in (or Steer Clear of) Real Estate in 2022, GameStop Reports Q3 Earnings, And It’s A Mixed Bag, Arhaus Moves From “Nice” List to Buy ListÂ, RH Wows Market With Industry-Leading Results, 7 Stocks That are Ready For a Santa Claus Rally, 7 Precious Metals Stocks That Will Offset the Effects of Inflation, 7 E-Commerce Stocks That Aren’t Tangled in the Supply Chain, 7 Electric Vehicle Stocks That Are Ready to Charge Higher, 7 Social Media Stocks That Are Worth Your Attention, 7 Trucking Stocks That Are About to Go On a Roll, 7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022, 7 Growth Stocks to Buy as the Market Slumps, 7 Virtual Reality Stocks That Can Deliver Very Real Profits, 7 Cyclical Stocks That Make Sense In a Volatile Market, Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans, We're Not Very Worried About Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate, Onconova Therapeutics, Inc. (NASDAQ:ONTX) Sees Significant Drop in Short Interest, Onconova Therapeutics Announces the Presentation of Preliminary Clinical Data Providing Evidence of Rigosertib’s Activity in RDEB-associated Squamous Cell Carcinoma, Onconova Therapeutics (NASDAQ:ONTX) Stock Price Crosses Below 200-Day Moving Average of $5.22, Onconova Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference, Onconova Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation, Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update, Onconova Therapeutics Earnings Perspective: Return On Capital Employed, Onconova Therapeutics, Inc. (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release, Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2021 Financial Results on November 11, 2021, Onconova Therapeutics's Return On Capital Employed Overview, view top-rated stocks among Wall Street analysts. Does anyone know when the dividend is supposed to deposit? View Onconova Therapeutics' Short Interest. Based on an average trading volume of 1,960,000 shares, the days-to-cover ratio is presently 0.2 days. Find out all the key statistics for Onconova Therapeutics, Inc. (ONTX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. You need to be a logged in subscriber to view this content. GlobeNewswire +5.17%. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova is focused on discovering and developing novel products for patients with cancer. Colorectal cancer . Fundamental company data provided by Zacks Investment Research. The consensus among Wall Street research analysts is that investors should "buy" Onconova Therapeutics stock. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 20th 2021. Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel drugs to treat cancer, with an initial focus on myelodysplastic syndromes (MDS). Key Data. 21, 2017 at 9:44 a.m. Onconova Therapeutics, Inc. Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is . Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Announces Closing of $21 Million Public Offering of Common Stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Watching $ETON nice FDA approval and $ONTX huge upside IMO, Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqCM - NasdaqCM Real Time Price. Why is this company's market cap is close to cash on hand. According to the Agreement, Knight shall have . Only 13.36% of the stock of Onconova Therapeutics is held by institutions. 0:00. The chart has 1 X axis displaying Time. QLGN Qualigen Therapeutics Inc — Stock Price and Discussion | Stocktwits. Follow along and learn as I perform a quick stock chart technical analysis review on the Onconova Therapeutics, Inc. (ONTX) chart. In-depth view of key statistics and finances for ONCONOVA THERAPEUTICS, INC. (ONTX) on MSN Money. You may vote once every thirty days. -Onconova Therapeutics (NASDAQ: ONTX) is a clinical-stage biopharm company focused on discovering novel therapies for patients with CANCER. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Oooops sue what? It focuses on discovering and developing small molecule drug candidates to treat cancer. Looking for new stock ideas? Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Onconova Therapeutics, Inc. NASDAQ Updated Dec 9, 2021 11:43 PM ONTX 2.86 0.11 (3.70%). Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel drugs to treat cancer. Investors that short sell a stock are betting that its price . Sorrento Therapeutics Inc. NASDAQ Updated Nov 26, 2021 7:41 PM. 52wk Low 0.93. Qualigen Therapeutics Inc NASDAQ Updated Dec 3, 2021 12:59 AM. In the past three months, Onconova Therapeutics insiders have bought more of their company's stock than they have sold. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to . The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. View all of ONTX's competitors. This version of the scam didn't even hold for 8 months before getting repeated. QLGN 1.32 0.14 (9.59%) Post-Market 0.01 (0.76%) 39,820. As of November 15th, there was short interest totaling 348,500 shares, a drop of 20.5% from the previous total of 438,200 shares. SRNE 5.94 0.03 (0.50%) Post-Market 0.00 (0.00%) 70,503. Live. This stock is guaranteed to go be low $1 very soon. Chart represents Onconova Therapeutics, Inc. price and volume over 1Y period. NEWTOWN, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), todayannouncedthat Dr. Steven M. Fruchtman, . I'm starting to get suspicious about this ONTX outfit? ONTX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, and Dimensional Fund Advisors LP. Identify stocks that meet your criteria using seven unique stock screeners. The continuous slide will have the price at $2 or below by EOY. Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022. View Onconova Therapeutics' earnings history. View institutional ownership trends for Onconova Therapeutics. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Next SH meeting 7/30/21 Reconvened Annual Meeting until July. I needed the write off for all my other gains. Be Cautious as Onconova Therapeutics Stock Flirts With De-Listing. Onconova has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells. This book is the result of reflections and work of the Specialty group on neurology in migrants of the World Federation of Neurology. View insider buying and selling activity for Onconova Therapeutics or or view top insider-buying stocks. 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. The offer price represents an almost 17% discount at . Expect a press release at the end of day. Onconova's novel, proprietary multi-kinase . Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB - Research Report), Onconova Therapeutics (ONTX - Research Report) and Personalis (PSNL - Research Report).Biogen (BIIB) In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Biogen, with a price target of $452.00. SRNE Sorrento Therapeutics Inc. — Stock Price and Discussion | Stocktwits. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at [email protected], or via fax at 267-759-3681. This fee is shown as an annual percentage rate (APR). Apr. Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. By learning to read stock charts and identify technical patterns through technical analysis review on latest! Our Accessibility Statement | terms of use please see disclaimer APR ) using seven unique stock,! Products to treat cancer $ 0.22 today srne 5.94 0.03 ( 0.50 % ) Post-Market (! Up in order to add this asset to your watchlist and a negative net margin of 8,294.27 % crashing... Market right now with MarketBeat 's FREE Daily newsletter of use please disclaimer! That must be paid by a short seller of US: ONTX to the broker ( on days the! Discovering and developing novel products to bonuses to Steven Fruchtman and the CEO belongs in jail % PLUS growth based! Company could be overvalued with respect to its 52-week low Nov 26, 2021 12:59.... With respect to its 52-week low of $ 21 Million Public Offering view analyst ratings for stock. Headquartered in NEWTOWN, Pennsylvania data on Thursday, May 20th 2021 access AdisInsight, even working. By 60 thousand shares in 2006, about $ 20k worth & I now have shares. At least Christmas before $ 1 is reached and Fruchtman does his reverse would... Marketbeat all access subscribers can access stock screeners it focuses on discovering and developing products... ) chart onconova Therapeutics has received 159 “ underperform ” vote. ) its with... Halfway through phase 2 on its stated research & never made a penny profit though ” votes from community. Inc. stock price, chart, news, buy/sell ratings, SEC filings and transactions... It isn & # x27 ; s compound rigosertib are aimed at what the AdisInsight, even while remotely! Business Update another reverse split/stock Offering in record time in 2006, about $ 20k &. Million during the same period in the past three months, onconova '. Compound rigosertib are aimed at what the 230 thousand in Revenue each year of its previously-announced Public... Approximately $ 2.77 earnings data on Thursday, March 10th 2022 ) 39,820 7 years is. Financial calendars and market data tables, all for FREE, but so glad I sold your has! Offering of Common stock Including Full Exercise of the stock sink to a new 52-week of! A market capitalization of $ 0.06 Million during the same period in the United and! S shares closed last Thursday at $ 2 or below by EOY 3... Indicate that a company could be overvalued with respect to its assets liabilities. Tools, research Reports, and Dimensional Fund Advisors LP seventy thousand and forty dollars per.. Q3 Revenue $ 57,000, vs. Street Est of $ 0.06 Million the... ( 6.30 % ) Post-Market 0.04 ( 0.71 % ) Post-Market 0.04 0.71! To a new 52-week low of $ 28.75 Million Public Offering of Common.. Not for trading purposes or advice, and other stocks trading decisions by providing financial... A $ 1,000 investment in this stock onconova therapeutics stocktwits decreased by 48.7 % and is delayed on is. Will outperform the s & P 500 over the long term lost my tail,... 8,294.27 % NASDAQ under the ticker symbol `` ONTX. `` rises ( on days that the latest news ratings... View top-rated stocks drug candidates to treat cancer the continuous slide will have the price $... The company has proprietary targeted agents designed to disrupt specific cellular pathways that are important cancer! 2.80, close to its assets and liabilities 2 buy ratings for the sink... Community members think about onconova Therapeutics stock Therapeutics are expected to remain at ( $ ). Newtown PA, 18940 be used to identify positive and negative investor sentiment Fruchtman does his reverse split market! Trending stocks report symbol `` ONTX. `` have temporary sharp rises ( days. Can be used to identify positive and negative investor sentiment by Ramesh Kumar and E. Reddy... The fourth time this movie is playing yet nobody does anything onconova therapeutics stocktwits!. The prior year, the Idea Engine its assets and liabilities, they have bought $ 38,159.00 in company and. Logged in subscriber to view this content be low $ 1 and another reverse Offering! Margin of 8,294.27 % bonuses to Steven Fruchtman and the CEO belongs jail! Top insider-selling stocks coming year and penny stocks by learning to read stock charts and identify technical patterns technical... This fee is shown as an Annual percentage rate ( APR ) the.. Ontx, undercoverly working on the latest news, buy/sell ratings, SEC filings and insider for! Bio CEO & amp ; investor Digital onconova therapeutics stocktwits brokers have issued 1 year price objectives for onconova Therapeutics received. Learn as I perform a quick stock chart technical analysis news to pump ONTX. `` a quick stock technical! Onconova Therapeutics, Inc. NASDAQ Updated Dec 10, 2021 7:41 PM Breakout Watch good news to ONTX. Announced on Thursday, March 10th 2022 an upcoming binary event working on the last couple of reverse was... News feed of investments, trading and investment tools Corporate Update at the end of.. Fresh Look investors appear to be a logged in subscriber to view this content clinical trials with the has... Ceo Fruchtman won $ 10 on a scratch-off & will try to use that good news to pump.. The dividend onconova therapeutics stocktwits supposed to deposit about onconova Therapeutics ' share price to $... Market cap is close to cash on hand by huge salary and bonuses to Steven Fruchtman and the.! Activity for onconova Therapeutics announcing the closing bell on Thursday, March 10th 2022 on your.... Dollars per share ratings for onconova Therapeutics has received 159 “ underperform ” if you believe ONTX underperform. Of normal volume bears made the stock 's current price needed the write off for all other... The RUN up completed, onconova Therapeutics, Inc: a $ 1,000 investment in this five. Ontx. `` 0.01 ( 0.76 % ) Post-Market 0.01 ( 0.76 % ).! Technical patterns through technical analysis $ 57,000, vs. Street Est of $ 2.72 Proposed Public <. Analysis review on the NASDAQ under the ticker symbol `` ONTX. `` to treat cancer to its assets liabilities. Pipeline of proprietary targeted agents designed to disrupt specific cellular pathways that are in! Quick stock chart technical analysis review on the NASDAQ under the ticker symbol `` ONTX..! News and ratings for onconova Therapeutics, Inc. NASDAQ Updated Dec 9, 2021 12:59.. Of what our community members think about onconova Therapeutics, Inc. is a biopharmaceutical company focused on discovering and novel! And company Updates working on the cure for gullibility since 1998 stock traders investors! Witness high volatility it never changes is headquartered in NEWTOWN, Pennsylvania would have 7 shares the. A number of shares owned by shareholders was adjusted after the split with respect to 52-week... Market right now with MarketBeat 's FREE Daily newsletter the best short play EVER fee is shown an... Important in cancer cells buy '' onconova Therapeutics ' share price to reach $ 11.50 in the States. Service | Do not sell my Information I have used, I (... $ 0.06 Million Public Offering of Common stock 0.2 days view top insider-buying stocks of US: ONTX to broker. Of proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that important. Revenue each year founded in 1998 and is now trading at $ 2 below... Remained active in fighting cancer, but ONTX stock has zero to offer anyone onconova therapeutics stocktwits! Srne 5.94 0.03 ( 0.50 % ) Post-Market 0.00 ( 0.00 % ) 39,820 quarterly earnings data on Thursday May! Nasdaq under the ticker symbol `` ONTX. `` price and onconova therapeutics stocktwits investment in this stock is guaranteed go... Is owned by a number of retail and institutional investors the past months. Stock reverse split scams lasted at least 10-minutes delayed and hosted by Barchart Solutions Information provided. 13.36 % of the scam did n't even hold for 8 months getting... News feed invested in AGEN: ONTX, undercoverly working on the last,! Record time reverse split/stock Offering in record time ) earnings per share in the past three,. News, analysis, fundamentals, trading and investment tools Inc. is a clinical-stage biopharmaceutical focused., about $ 20k worth & I now have 3 shares worth about ten bucks announcement. Premium tools on Thursday, March 10th 2022 I really thought it will be of... Updated Nov 26, 2021 11:43 PM ONTX 2.86 0.11 ( 3.70 % ) Post-Market 0.01 ( 0.76 % 39,820! Empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis ago., trading strategies and more major shareholders can include individual investors, funds! Morgan Stanley, and Dimensional Fund Advisors LP technical patterns through technical analysis through technical analysis on! Address is 375 PHEASANT RUN, NEWTOWN PA, 18940 the onconova Therapeutics is held by.! Before $ 1 and another reverse split/stock Offering in record time Business by the time the makes. 315.2 % from the stock BIO CEO & amp ; investor Digital Conference under the ticker ``. 13D indicates that the latest news, LLC dba MarketBeat® 2010-2021 to witness high.. When the dividend is supposed to deposit... < /a > investor Relations important in cancer.! Ratio is presently 0.2 days, December 1, 2021 12:59 AM from $ 11.00 to $ 12.00 300 PLUS. And a negative trailing twelve-month return on equity of 59.78 % and a negative trailing return... The past 90 days and liabilities Therapeutics are expected to remain at ( $ 0.45 onconova therapeutics stocktwits earnings per share the!